AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05018858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05293756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMA-BP Intervention
Description: Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor.
Study NCT04299022 — intervention group
Intervention type: OTHER
Intervention: Vivigen Cellular Bone Matrix
Description: Allograft bone matrix
Study NCT05178485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: FDA approved drug
Study NCT05178485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: FDA approved
Study NCT05522595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S360
Description: In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator.
Study NCT06543342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander Brief Motivational Intervention
Description: Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
Study NCT06304779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine.
Study NCT06304779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
Study NCT06432166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-hydroxybenzylamine acetate
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
Study NCT06432166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken three times per day for 16 weeks.
Study NCT04994678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
Study NCT04994678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Aerobic Exercise Training
Description: Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
Study NCT04379778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Progressive moderate to high intensity aerobic exercise.
Study NCT05124171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older
Study NCT05124171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK
Description: ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older
Study NCT05124171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Description: ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older
Study NCT05477797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib DX/Lenalidomide DX
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Study NCT05477797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixazomib DX/Lenalidomide DX
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Study NCT05301309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding consultation
Description: Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
Study NCT05301309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding consultation
Description: Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
Study NCT05126849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogenic transplantation
Description: 1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine.
Study NCT06405477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine
Description: Capsules of 3 grams of L-arginine per Dose
Study NCT06405477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Capsules of 3 grams of L-arginine per Dose
Study NCT06405477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 3 grams of maize Starch per Dose
Study NCT06405477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules of 3 grams of maize Starch per Dose
Study NCT04991545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Infrared (Active IRD/ IRRIS) device
Description: The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared
Study NCT05683288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
Study NCT05683288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
Study NCT05683288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250W infrared application
Description: For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
Study NCT05683288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
Study NCT05558748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG-guided Caudal block
Description: USG-guided Caudal block after general anesthesia
Study NCT06143982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intensive Trauma Treatment
Description: BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
Study NCT05683288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Cervical strengthening and stretching exercises five days a week will given
Study NCT05262283 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was made.
Study NCT05944627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-OA Kit Inj.
Description: FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
Study NCT05944627 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo administration in Phase 2a clinical trial
Study NCT04807257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Auger Molecular Therapy (AMT)
Description: The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
Study NCT05884944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Interventional Group- OMM- Muscle energy
Description: The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
Study NCT05567510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study NCT05800912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative photography
Description: Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours).
Study NCT05800912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional learning
Description: A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant.
Study NCT05104970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SunnyD insta ampoule
Description: Cholecalciferol 200000 IU insta ampoule
Study NCT05104970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SunnyD STAT softgel capsule
Description: Cholecalciferol 200000 IU softgel capsule
Study NCT05104970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SunnyD insta ampoule
Description: Olive oil
Study NCT05104970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SunnyD STAT softgel capsule
Description: Olive oil
Study NCT05443815 — intervention group
Intervention type: DEVICE
Intervention: HaemoCer-PLUS
Description: HaemoCer-PLUS
Study NCT04564677 — intervention group
Intervention type: DEVICE
Intervention: Ifabond (Péters surgical)
Description: Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
Study NCT05910008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: O-Arm Stereotactic imaging
Description: Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
Study NCT05910008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Stereotactic imaging
Description: Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
Study NCT05686213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined aerobic exercise + resistance exercise intervention (AE + RE)
Description: The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
Study NCT05686213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise prior to daily radiotherapy sessions (ExPR)
Description: Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
Study NCT04200027 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
Study NCT05558748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG-guided Ilioinguinal/Iliohypogastric block
Description: USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
Study NCT06363604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VOMEI + PVI + linear ablation of mitral isthmus
Description: The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
Study NCT05679271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous stenting
Description: venous stenting associated to antiaggregation protocol
Study NCT05679271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: observation: no treatment
Study NCT05543083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy followed by Exercise Training
Description: 6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
Study NCT05543083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training followed by Cognitive-Behavioral Therapy
Description: 6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
Study NCT05543083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy Only
Description: 6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
Study NCT05543083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Only
Description: 6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
Study NCT06363604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VOMEI + PVI + linear ablation of mitral isthmus
Description: The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
Study NCT06363604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior wall isolation
Description: PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
Study NCT06372600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy device
Description: In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.